Treatment of Alzheimer's and Dementia With the Metabolism, Infections, Nutrition, Drug Elimination (MIND) Protocol

Dementia Clinical Trial

— MIND  

Official title:

Effective Treatment of Alzheimer's and Dementia With the MIND Protocol

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02260167
• Other study ID #: PAN-ALZ002
• Status: Completed
• Phase: N/A
• Start date: September 2014
• Est. completion date: December 2017

Study information

• Verified date: May 2020
• Source: Practitioners Alliance Network
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Treating with measures that may improve metabolic functioning of neurons in an integrated protocol

Description:

Most organ failure results in modest drops in function until over 50% of function is lost. At a certain point, even modest drops in physiologic activity result in dramatic drops in clinical function. Though less homogeneous than in other organs, clinical experience and the literature suggests a similar process occurs in the brain. The hypothesis is that by using an integrated protocol to, essentially, "tune up" neuronal function, a 5-10 % improvement in metabolic functioning may translate to significant improvement in clinical functioning. This tune-up will include "MIND":

M- Metabolism-- optimizing hormonal function I- Infections-- looking for and eliminating N- Nutritional and herbal support D- Drugs- Weaning subjects off unneeded medications

Recruitment information / eligibility

• Status: Completed
• Enrollment: 25
• Est. completion date: December 2017
• Est. primary completion date: December 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• A diagnosis of Alzheimer's and/or dementia with an MMSE score over 12 or being ambulatory and able to travel outside the home with assistance.

• Must have a caregiver living with them.

Exclusion Criteria:

• Overt progressive and severe causes of secondary dementia such as metastatic brain cancers, or severe overt infectious encephalopathies or severe autoimmune illness.

• Also, severe life threatening illnesses which would make them unlikely to be alive after 6-12 months

Related Conditions & MeSH terms

• Alzheimer Disease
• Alzheimer's Disease
• Dementia

Intervention

Other:
• A mix of natural treatments and medications

Locations

Country	Name	City	State
United States	PAN	Kailua	Hawaii

Sponsors (1)

Lead Sponsor	Collaborator
Practitioners Alliance Network

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Montreal Cognitive Assessment (MoCA)	Looking to see what percent of patients show improvement	6 months
Secondary	Mini Mental Status Exam (MMSE)		6 months
Secondary	Alzheimer's Disease Assessment Scale- Activities of Daily Living (ADAS-ADL)		6 months